Flortaucipir PET Imaging in Subjects With FTD

Inclusion Criteria:

- Have provided informed consent or have a legally authorized (LAR) provide consent for
study procedures

- Have had volumetric brain MRI obtained in site's companion protocol within one year of
enrollment

- Can tolerate PET scan procedures

Exclusion Criteria:

- Have clinically significant cardiac, hepatic, renal, pulmonary, metabolic, or
endocrine disturbances that pose potential safety risk

- Have history of risk factors for Torsades de Pointes (TdP) or taking medication known
to cause QT prolongation

- Have history of drug or alcohol dependence within the last year

- Are females of childbearing potential who are not surgically sterile, not refraining
from sexual activity, or not using reliable contraception

- Have history of relevant severe drug allergy or hypersensitivity

- Have received an investigational medication under FDA IND protocol within 30 days of
planned imaging session

- Have received a radiopharmaceutical for imaging/therapy within 24 hours of imaging
session

- Possess PET scan evidence of amyloid deposition

- Determined by the investigator to be unsuitable for this type of study